One calcitriol dose transiently increases Helios+FoxP3+ T cells and ameliorates autoimmune demyelinating disease

Journal of Neuroimmunology

Volumn 263, Issue 1-2, 2013, Pages 64-74

  Nashold, Faye E ^a   Nelson, Corwin D ^a   Brown, Lauren M ^a   Hayes, Colleen E ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Autoimmunity; Encephalomyelitis; Methylprednisolone; Multiple sclerosis; Vitamin D

Indexed keywords

CALCITRIOL; COLECALCIFEROL; MERCAPTOPURINE; METHYLPREDNISOLONE; PLACEBO; TRANSCRIPTION FACTOR FOXP3; VITAMIN D;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; LYMPHOCYTE COUNT; MALE; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; PILOT STUDY; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SEX DIFFERENCE; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

AUTOIMMUNITY; ENCEPHALOMYELITIS; METHYLPREDNISOLONE; MULTIPLE SCLEROSIS; VITAMIN D;

ANIMALS; CALCITRIOL; CATTLE; DNA-BINDING PROTEINS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; LYMPHOCYTE COUNT; MALE; MICE; RANDOM ALLOCATION; T-LYMPHOCYTE SUBSETS; TRANSCRIPTION FACTORS; UP-REGULATION;

EID: 84884815731     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2013.07.016     Document Type: Article

References (74)

1. Adams J.S., Gacad M.A. Characterization of 1 alpha-hydroxylation of vitamin D3 sterols by cultured alveolar macrophages from patients with sarcoidosis. J. Exp. Med. 1985, 161:755-765.
2. Almeras L., Meresse B., Seze J., De Lefranc D., Dubucquoi S., Fajardy I., et al. Interleukin-10 promoter polymorphism in multiple sclerosis: association with disease progression. Eur. Cytokine Netw. 2002, 13:200-206.
3. Annweiler C., Fantino B., Gautier J., Beaudenon M., Thiery S., Beauchet O. Cognitive effects of vitamin D supplementation in older outpatients visiting a memory clinic: a pre-post study. J. Am. Geriatr. Soc. 2012, 60:793-795.
4. Annweiler C., Rolland Y., Schott A.M., Blain H., Vellas B., Herrmann F.R., et al. Higher vitamin D dietary intake is associated with lower risk of Alzheimer's disease: a 7-year follow-up. J. Gerontol. Ser. A Biol. Sci. Med. Sci. 2012, 67:1205-1211.
5. Antel J., Antel S., Caramanos Z., Arnold D.L., Kuhlmann T. Primary progressive multiple sclerosis: part of the MS disease spectrum or separate disease entity?. Acta Neuropathol. 2012, 123:627-638.
6. Baschant U., Tuckermann J. The role of the glucocorticoid receptor in inflammation and immunity. J. Steroid Biochem. Mol. Biol. 2010, 120:69-75.
7. Bechmann I., Mor G., Nilsen J., Eliza M., Nitsch R., Naftolin F. FasL (CD95L, Apo1L) is expressed in the normal rat and human brain: evidence for the existence of an immunological brain barrier. Glia 1999, 27:62-74.
8. Beer T.M. Development of weekly high-dose calcitriol based therapy for prostate cancer. Urol. Oncol. 2003, 21:399-405.
9. Beer T.M., Munar M., Henner W.D. A Phase I trial of pulse calcitriol in patients with refractory malignancies: pulse dosing permits substantial dose escalation. Cancer 2001, 91:2431-2439.
10. Bell N.H., Stern P.H., Pantzer E., Sinha T.K., DeLuca H.F. Evidence that increased circulating 1 alpha, 25-dihydroxyvitamin D is the probable cause for abnormal calcium metabolism in sarcoidosis. J. Clin. Invest. 1979, 64:218-225.
11. Bieganowska K.D., Ausubel L.J., Modabber Y., Slovik E., Messersmith W., Hafler D.A. Direct ex vivo analysis of activated, Fas-sensitive autoreactive T cells in human autoimmune disease. J. Exp. Med. 1997, 185:1585-1594.
12. Bischoff-Ferrari H.A., Shao A., Dawson-Hughes B., Hathcock J., Giovannucci E., Willett W.C. Benefit-risk assessment of vitamin D supplementation. Osteoporos. Int. 2010, 21:1121-1132.
13. Burton J.M., O'Connor P.W., Hohol M., Beyene J. Oral versus intravenous steroids for treatment of relapses in multiple sclerosis. Cochrane Database Syst. Rev. 2009, CD006921.
14. Cantorna M.T., Woodward W.D., Hayes C.E., DeLuca H.F. 1,25-Dihydroxyvitamin D3 is a positive regulator for the two anti-encephalitogenic cytokines TGF-beta 1 and IL-4. J. Immunol. 1998, 160:5314-5319.
15. Chan J., Ban E.J., Chun K.H., Wang S., McQualter J., Bernard C., et al. Methylprednisolone induces reversible clinical and pathological remission and loss of lymphocyte reactivity to myelin oligodendrocyte glycoprotein in experimental autoimmune encephalomyelitis. Autoimmunity 2008, 41:405-413.
16. Charmandari E., Tsigos C., Chrousos G. Endocrinology of the stress response. Annu. Rev. Physiol. 2005, 67:259-284.
17. Comi C., Fleetwood T., Dianzani U. The role of T cell apoptosis in nervous system autoimmunity. Autoimmun. Rev. 2012, 12:150-156.
18. de Jong B.A., Schrijver H.M., Huizinga T.W., Bollen E.L., Polman C.H., Uitdehaag B.M., et al. Innate production of interleukin-10 and tumor necrosis factor affects the risk of multiple sclerosis. Ann. Neurol. 2000, 48:641-646.
19. Deluca G.C., Kimball S.M., Kolasinski J., Ramagopalan S.V., Ebers G.C. Review. The role of vitamin D in nervous system health and disease. Neuropathol. Appl. Neurobiol. 2013, 39:458-484.
20. Dutta R., Trapp B.D. Mechanisms of neuronal dysfunction and degeneration in multiple sclerosis. Prog. Neurobiol. 2011, 93:1-12.
21. Dyment D.A., Cader M.Z., Chao M.J., Lincoln M.R., Morrison K.M., Disanto G., et al. Exome sequencing identifies a novel multiple sclerosis susceptibility variant in the TYK2 gene. Neurology 2012, 79:406-411.
22. Fakih M.G., Trump D.L., Muindi J.R., Black J.D., Bernardi R.J., Creaven P.J., et al. A phase I pharmacokinetic and pharmacodynamic study of intravenous calcitriol in combination with oral gefitinib in patients with advanced solid tumors. Clin. Cancer Res. 2007, 13:1216-1223.
23. Flugel A., Schwaiger F.W., Neumann H., Medana I., Willem M., Wekerle H., et al. Neuronal FasL induces cell death of encephalitogenic T lymphocytes. Brain Pathol. 2000, 10:353-364.
24. Garcion E., Wion-Barbot N., Montero-Menei C.N., Berger F., Wion D. New clues about vitamin D functions in the nervous system. Trends Endocrinol. Metab. 2002, 13:100-105.
25. Getnet D., Grosso J.F., Goldberg M.V., Harris T.J., Yen H.R., Bruno T.C., et al. A role for the transcription factor Helios in human CD4(+)CD25(+) regulatory T cells. Mol. Immunol. 2010, 47:1595-1600.
26. Gorman S., Kuritzky L.A., Judge M.A., Dixon K.M., McGlade J.P., Mason R.S., et al. Topically applied 1,25-dihydroxyvitamin D3 enhances the suppressive activity of CD4+CD25+ cells in the draining lymph nodes. J. Immunol. 2007, 179:6273-6283.
27. Hayes C.E., Nashold F.E., Mayne C.G., Spanier J.A., Nelson C.D. Vitamin D and multiple sclerosis. Vitamin D 2011, 1843-1877. Elsevier, San Diego, California. Third ed. D. Feldman, J.W. Pike, J.S. Adams (Eds.).
28. Jeffery L.E., Burke F., Mura M., Zheng Y., Qureshi O.S., Hewison M., et al. 1,25-Dihydroxyvitamin D3 and IL-2 combine to inhibit T cell production of inflammatory cytokines and promote development of regulatory T cells expressing CTLA-4 and FoxP3. J. Immunol. 2009, 183:5458-5467.
29. Kalueff A.V., Eremin K.O., Tuohimaa P. Mechanisms of neuroprotective action of vitamin D(3). Biochemistry (Mosc.) 2004, 69:738-741.
30. Kent S.J., Karlik S.J., Cannon C., Hines D.K., Yednock T.A., Fritz L.C., et al. A monoclonal antibody to alpha 4 integrin suppresses and reverses active experimental allergic encephalomyelitis. J. Neuroimmunol. 1995, 58:1-10.
31. Kohji T., Matsumoto Y. Coexpression of Fas/FasL and Bax on brain and infiltrating T cells in the central nervous system is closely associated with apoptotic cell death during autoimmune encephalomyelitis. J. Neuroimmunol. 2000, 106:165-171.
32. Kohji T., Tanuma N., Aikawa Y., Kawazoe Y., Suzuki Y., Kohyama K., et al. Interaction between apoptotic cells and reactive brain cells in the central nervous system of rats with autoimmune encephalomyelitis. J. Neuroimmunol. 1998, 82:168-174.
33. Lee J.H., O'Keefe J.H., Bell D., Hensrud D.D., Holick M.F. Vitamin D deficiency an important, common, and easily treatable cardiovascular risk factor?. J. Am. Coll. Cardiol. 2008, 52:1949-1956.
34. Liu Y., Teige I., Birnir B., Issazadeh-Navikas S. Neuron-mediated generation of regulatory T cells from encephalitogenic T cells suppresses EAE. Nat. Med. 2006, 12:518-525.
35. Loser K., Beissert S. Regulation of cutaneous immunity by the environment: an important role for UV irradiation and vitamin D. Int. Immunopharmacol. 2009, 9:587-589.
36. Luomala M., Lehtimaki T., Huhtala H., Ukkonen M., Koivula T., Hurme M., et al. Promoter polymorphism of IL-10 and severity of multiple sclerosis. Acta Neurol. Scand. 2003, 108:396-400.
37. Martinez Doncel A., Rubio A., Arroyo R., de las Heras V., Martin C., Fernandez-Arquero M., Neuroimmunol J., et al. Interleukin-10 polymorphisms in Spanish multiple sclerosis patients. J. Neuroimmunol. 2002, 131:168-172.
38. Mayne C.G., Spanier J.A., Relland L.M., Williams C.B., Hayes C.E. 1,25-Dihydroxyvitamin D3 acts directly on the T lymphocyte vitamin D receptor to inhibit experimental autoimmune encephalomyelitis. Eur. J. Immunol. 2011, 41:822-832.
39. McFarlin D.E., Blank S.E., Kibler R.F. Recurrent experimental allergic encephalomyelitis in the Lewis rat. J. Immunol. 1974, 113:712-715.
40. McRae B.L., Kennedy M.K., Tan L.J., Dal Canto M.C., Picha K.S., Miller S.D. Induction of active and adoptive relapsing experimental autoimmune encephalomyelitis (EAE) using an encephalitogenic epitope of proteolipid protein. J. Neuroimmunol. 1992, 38:229-240.
41. Meier D.S., Balashov K.E., Healy B., Weiner H.L., Guttmann C.R. Seasonal prevalence of MS disease activity. Neurology 2010, 75:799-806.
42. Mkhikian H., Grigorian A., Li C.F., Chen H.L., Newton B., Zhou R.W., et al. Genetics and the environment converge to dysregulate N-glycosylation in multiple sclerosis. Nat. Commun. 2011, 2:334.
43. Morales-Tirado V., Wichlan D.G., Leimig T.E., Street S.E., Kasow K.A., Riberdy J.M. 1alpha,25-dihydroxyvitamin D3 (vitamin D3) catalyzes suppressive activity on human natural regulatory T cells, uniquely modulates cell cycle progression, and augments FOXP3. Clin. Immunol. 2011, 138:212-221.
44. Mowry E.M., Waubant E., McCulloch C.E., Okuda D.T., Evangelista A.A., Lincoln R.R., et al. Vitamin D status predicts new brain magnetic resonance imaging activity in multiple sclerosis. Ann. Neurol. 2012, 72:234-240.
45. Myhr K.M., Mellgren S.I. Corticosteroids in the treatment of multiple sclerosis. Acta Neurol. Scand. Suppl. 2009, 73-80.
46. Myhr K.M., Vagnes K.S., Maroy T.H., Aarseth J.H., Nyland H.I., Vedeler C.A. Interleukin-10 promoter polymorphisms in patients with multiple sclerosis. J. Neurol. Sci. 2002, 202:93-97.
47. Nashold F.E., Miller D.J., Hayes C.E. 1,25-Dihydroxyvitamin D3 treatment decreases macrophage accumulation in the CNS of mice with experimental autoimmune encephalomyelitis. J. Neuroimmunol. 2000, 103:171-179.
48. Nashold F.E., Hoag K.A., Goverman J., Hayes C.E. Rag-1-dependent cells are necessary for 1,25-dihydroxyvitamin D(3) prevention of experimental autoimmune encephalomyelitis. J. Neuroimmunol. 2001, 119:16-29.
49. Nashold F.E., Spach K.M., Spanier J.A., Hayes C.E. Estrogen controls vitamin D3-mediated resistance to experimental autoimmune encephalomyelitis by controlling vitamin D3 metabolism and receptor expression. J. Immunol. 2009, 183:3672-3681.
50. Ontaneda D., Hyland M., Cohen J.A. Multiple sclerosis: new insights in pathogenesis and novel therapeutics. Annu. Rev. Med. 2012, 63:389-404.
51. Pedersen L.B., Nashold F.E., Spach K.M., Hayes C.E. 1,25-Dihydroxyvitamin D3 reverses experimental autoimmune encephalomyelitis by inhibiting chemokine synthesis and monocyte trafficking. J. Neurosci. Res. 2007, 85:2480-2490.
52. Pender M.P. Treating autoimmune demyelination by augmenting lymphocyte apoptosis in the central nervous system. J. Neuroimmunol. 2007, 191:26-38.
53. Royal W., Mia Y., Li H., Naunton K. Peripheral blood regulatory T cell measurements correlate with serum vitamin D levels in patients with multiple sclerosis. J. Neuroimmunol. 2009, 213:135-141.
54. Saresella M., Marventano I., Speciale L., Ruzzante S., Trabattoni D., Della Bella S., et al. Programmed cell death of myelin basic protein-specific T lymphocytes is reduced in patients with acute multiple sclerosis. J. Neuroimmunol. 2005, 166:173-179.
55. Smolders J., Thewissen M., Peelen E., Menheere P., Cohen Tervaert J.W., Damoiseaux J., et al. Vitamin D status is positively correlated with regulatory T cell function in patients with multiple sclerosis. PLoS One 2009, 4:e6635.
56. Spach K.M., Hayes C.E. Vitamin D3 confers protection from autoimmune encephalomyelitis only in female mice. J. Immunol. 2005, 175:4119-4126.
57. Spach K.M., Pedersen L.B., Nashold F.E., Kayo T., Yandell B.S., Prolla T.A., et al. Gene expression analysis suggests that 1,25-dihydroxyvitamin D3 reverses experimental autoimmune encephalomyelitis by stimulating inflammatory cell apoptosis. Physiol. Genomics 2004, 18:141-151.
58. Spach K.M., Nashold F.E., Dittel B.N., Hayes C.E. IL-10 signaling is essential for 1,25-dihydroxyvitamin D3-mediated inhibition of experimental autoimmune encephalomyelitis. J. Immunol. 2006, 177:6030-6037.
59. Stadelmann C. Multiple sclerosis as a neurodegenerative disease: pathology, mechanisms and therapeutic implications. Curr. Opin. Neurol. 2011, 24:224-229.
60. Stumpf W.E., Sar M., Clark S.A., DeLuca H.F. Brain target sites for 1,25-dihydroxyvitamin D3. Science 1982, 215:1403-1405.
61. Teitelbaum D., Arnon R., Sela M. Immunomodulation of experimental autoimmune encephalomyelitis by oral administration of copolymer 1. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:3842-3847.
62. Thornton A.M., Korty P.E., Tran D.Q., Wohlfert E.A., Murray P.E., Belkaid Y., et al. Expression of Helios, an Ikaros transcription factor family member, differentiates thymic-derived from peripherally induced Foxp3+ T regulatory cells. J. Immunol. 2010, 184:3433-3441.
63. Ting H.-J., Lee Y.-F. Vitamin D and Oxidative Stress. Vitamin D: Oxidation, Immunity, and Aging 2012, 131-149. Taylor & Francis Group, CRC Press. A.F. Gombart (Ed.).
64. van Winsen L.M., Polman C.H., Dijkstra C.D., Tilders F.J., Uitdehaag B.M. Suppressive effect of glucocorticoids on TNF-alpha production is associated with their clinical effect in multiple sclerosis. Mult. Scler. 2010, 16:500-502.
65. Vieth R. What is the optimal vitamin D status for health?. Prog. Biophys. Mol. Biol. 2006, 92:26-32.
66. Wang F., Wan L., Zhang C., Zheng X., Li J., Chen Z.K. Tim-3-Galectin-9 pathway involves the suppression induced by CD4+CD25+ regulatory T cells. Immunobiology 2009, 214:342-349.
67. Wekerle H., Hohlfeld R. Molecular oracles for multiple sclerosis therapy. Nat. Med. 2010, 16:376-377.
68. Wing K., Sakaguchi S. Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nat. Immunol. 2010, 11:7-13.
69. Wingerchuk D.M., Lesaux J., Rice G.P., Kremenchutzky M., Ebers G.C. A pilot study of oral calcitriol (1,25-dihydroxyvitamin D3) for relapsing-remitting multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 2005, 76:1294-1296.
70. Yanagisawa J., Yanagi Y., Masuhiro Y., Suzawa M., Watanabe M., Kashiwagi K., et al. Convergence of transforming growth factor-beta and vitamin D signaling pathways on SMAD transcriptional coactivators. Science 1999, 283:1317-1321.
71. Yu M., Nishiyama A., Trapp B.D., Tuohy V.K. Interferon-beta inhibits progression of relapsing-remitting experimental autoimmune encephalomyelitis. J. Neuroimmunol. 1996, 64:91-100.
72. Zabransky D.J., Nirschl C.J., Durham N.M., Park B.V., Ceccato C.M., Bruno T.C., et al. Phenotypic and functional properties of Helios+regulatory T cells. PLoS One 2012, 7:e34547.
73. Zerwekh J.E., Pak C.Y., Kaplan R.A., McGuire J.L., Upchurch K., Breslau N., et al. Pathogenetic role of 1 alpha,25-dihydroxyvitamin D in sarcoidosis and absorptive hypercalciuria: different response to prednisolone therapy. J. Clin. Endocrinol. Metab. 1980, 51:381-386.
74. Zhu C., Anderson A.C., Schubart A., Xiong H., Imitola J., Khoury S.J., et al. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat. Immunol. 2005, 6:1245-1252.